



Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference

May 24, 2021

Preclinical Data Supports Continued Advancement of SZN-1326 and SZN-043 Toward First-in-Human Clinical Studies in 2022

SOUTH SAN FRANCISCO, Calif., May 24, 2021 -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that data from preclinical studies of its two lead Wnt-modulating antibody programs were presented in six oral and poster presentations during [Digestive Disease Week 2021](#).

Of the six presentations, two discussed data from studies of SZN-1326, a bi-specific full-length human antibody targeting Fzd5/8 and Lrp6 receptors in development for the treatment of inflammatory bowel disease (IBD). Four presentations discussed data from studies of SZN-043, a hepatocyte-targeted R-spondin mimetic for severe alcoholic hepatitis. A replay of the oral presentation and copies of the ePosters will be posted in the Investors & Media section of Surrozen's website when available.

"We are developing and advancing our SWAP and SWEETS platforms with the goal of realizing the full potential of the Wnt pathway and unlocking the body's regenerative power to treat disease and injury. We remain focused on our ongoing efforts to develop a broad pipeline of first in class drug candidates, utilizing our tissue-specific antibodies, to help patients across multiple disease areas," commented Craig Parker, President and Chief Executive Officer of Surrozen. "The data from these preclinical studies of SZN-1326 and SZN-043 are highly encouraging and support continued advancement of both programs toward our first in human clinical studies, planned to begin in 2022."

SZN-1326 Presentations

In an oral presentation titled, "SZN-1326, a Wnt signal activator, improved epithelial healing and ameliorated colitis in an acute DSS model," data showed SZN-1326's ability to promote mucosal healing and reduce inflammation. As part of the study, mice were subjected to dextran sulfate sodium (DSS) and developed severe colitis. Treatment with SZN-1326 resulted in improved body weight, repaired damaged colon epithelium, and decreased serum and colon inflammatory cytokine markers without causing hyperplasia in healed epithelium or small intestine.

In a poster presentation titled, "SZN-1326 Promotes Colonic Mucosal Healing in an Acute Injury Model of IBD by Expanding the Progenitor Pool and Accelerating Differentiation," data showed mechanisms underlying the molecule's ability to promote mucosal healing by inducing stem and progenitor cell expansion that ultimately accelerates epithelial repair and reduces inflammation.

SZN-043 Presentations

In an oral presentation titled, "SZN-043, a Hepatocyte-targeted R-spondin Mimetic, Stimulates Hepatocyte Proliferation in an Acute Alcoholic Hepatitis Model," the data showed the potential of SZN-043 to stimulate hepatocyte-specific cell regeneration, to activate the Wnt signaling pathway and to improve hepatic function in aging mice after a prolonged chronic binge ethanol treatment.

In an oral presentation titled, "SZN-043, a Hepatocyte-targeted R-spondin Mimetic, Induces Hepatocyte Proliferation in an Acute Acetaminophen-induced Liver Injury Model," results demonstrated SZN-043 can induce hepatocyte-specific regeneration in response to an acetaminophen overdose reducing the area of necrosis.

In a poster presentation titled, "SZN-043, a Hepatocyte-Targeted R-spondin Mimetic, Promotes Transient Hepatocyte Proliferation and Zonal Gene Expression Changes in Mice," results demonstrated the program's ability to target hepatocytes and promote their proliferation, suggesting its utility as a regenerative therapy for liver diseases.

In a poster presentation titled, "Pharmacokinetics, Pharmacodynamics, and Toxicology of SZN-043, a Hepatocyte-targeted Wnt-potentiator, in Non-human Primates," data demonstrated that non-human primates could be dosed up to 125 mg/kg twice weekly for 2 weeks without adverse effects. SZN-043 showed target-mediated pharmacology and the pharmacokinetics of SZN-043 were consistent with that of an IgG-based molecule binding to the hepatocyte membrane protein ASGR1.

About Wnt Signaling

Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including liver, intestine, lung, kidney, retina, central nervous system, cochlea, bone, and others. Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries. Surrozen's platform and proprietary technologies have the potential to overcome the limitations in pursuing the Wnt pathway as a therapeutic strategy.

About Surrozen

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body's existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit surrozen.com.

Additional Information

In connection with the Business Combination, the Company has filed with the U.S. Securities and Exchange Commission's ("SEC") a Registration Statement on Form S-4 (the "Registration Statement"), which includes a preliminary prospectus noted above with respect to the securities of CHFV to be issued in connection with the Business Combination to Surrozen stockholders and as well as a proxy statement with respect to the shareholder meeting of CHFV to vote on the Business Combination and related matters. CHFV will mail a definitive proxy statement/final prospectus and other relevant documents to its shareholders after the Registration Statement is declared effective by the SEC. This communication is not a substitute for the Registration Statement, the definitive proxy statement/final prospectus or any other document that CHFV will send to its shareholders in connection with the Business Combination. The definitive proxy statement/final prospectus will contain important information about CHFV, Surrozen and their respective business and related risks, the combined company, including pro forma financial information and the proposed Business Combination and related matters. Investors and security holders of CHFV are advised to read, when available, the proxy

statement/prospectus in connection with CHFV's solicitation of proxies for its extraordinary general meeting of shareholders to be held to approve the Business Combination (and related matters) because the proxy statement/prospectus will contain important information about the Business Combination and the parties to the Business Combination. Investors and security holders of Surrozen are advised to read, when available, the proxy statement/prospectus in connection with the written consent of Surrozen stockholders. The definitive proxy statement/final prospectus will be mailed to shareholders of CHFV as of a record date to be established for voting on the Business Combination. Shareholders will also be able to obtain copies of the proxy statement/prospectus, without charge, once available, at the SEC's website at www.sec.gov or by directing a request to: Consonance-HFV Acquisition Corp., 1 Palmer Square, Suite 305, Princeton, NJ.

Participants in the Solicitation

CHFV, Surrozen and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of CHFV's shareholders in connection with the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of CHFV's directors and officers in CHFV's filings with the SEC, including the Registration Statement filed with the SEC by CHFV, which includes the preliminary proxy statement of CHFV for the Business Combination, and such information and names of Surrozen's directors and executive officers is also in the Registration Statement filed with the SEC by CHFV.

Forward Looking Statements

Certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the Business Combination between CHFV and Surrozen and the potential for, data regarding and benefits of the Wnt pathway. These statements are based on the current expectations of CHFV's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of CHFV and Surrozen. These statements are subject to a number of risks and uncertainties regarding CHFV's businesses and the Business Combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the inability of the parties to consummate the Business Combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination; the receipt of an unsolicited offer from another party

for an alternative business transaction that could interfere with the Business Combination; the risk that the approval of the shareholders of CHFV or the stockholders of Surrozen for the potential transaction is not obtained; failure to realize the anticipated benefits of the Business Combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of CHFV and Surrozen; the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; the ability of the combined company to grow and manage growth profitably and retain its key employees; the amount of redemption requests made by CHFV's shareholders; the inability to obtain or maintain the listing of the post-acquisition company's securities on Nasdaq following the Business Combination; costs related to the Business Combination; risks related to the matters set forth in the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies, issued by the Division of Corporate Finance of the SEC on April 12, 2021; and those factors discussed in the Registration Statement and in CHFV's annual report on Form 10-K for the year ended December 31, 2020 (as amended and restated), and other filings with the SEC. There may be additional risks that CHFV presently does not know or that CHFV currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide CHFV's expectations, plans or forecasts of future events and views as of the date of this communication. CHFV anticipates that subsequent events and developments will cause CHFV's assessments to change. However, while CHFV may elect to update these forward-looking statements at some point in the future, CHFV specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing CHFV's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Disclaimer

This communication is for informational purposes only and is neither a proxy statement, nor a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction, nor an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the Business Combination or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

###

Media Contact:

Ian Stone, Managing Director
CanaleComm
Tel.: (619) 518-3518

[Email: ian.stone@canalecomm.com](mailto:ian.stone@canalecomm.com)